Evidence map›Paper›PMID 27412597›Full record

ArticleJournal of virology2016

Biochemical and Structural Insights into the Preference of Nairoviral DeISGylases for Interferon-Stimulated Gene Product 15 Originating from Certain Species.

M K Deaton, J V Dzimianski, C M Daczkowski, G K Whitney, N J Mank, M M Parham, E Bergeron, S D Pegan

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. ISG15: It's Complicated.Journal of molecular biology · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M K DeatonDepartment of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, USA.
J V DzimianskiDepartment of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, USA.
C M DaczkowskiDepartment of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, USA.
G K WhitneyDepartment of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, USA.
N J MankDepartment of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, USA.ORCID 0000-0002-8684-8197
M M ParhamDepartment of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, USA.
E BergeronViral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-3398-8628
S D PeganDepartment of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, USA spegan@uga.edu.
University of Georgia · USCenters for Disease Control and Prevention · US

Funding

Origin of the innate immunity suppression caused by nairovirus' protease activityR01AI109008 · NIAID · UNIVERSITY OF GEORGIA · PI PEGAN, SCOTT DUSAN · 2014 to 2018
$1.6M
NIAID NIH HHS R01 AI109008
6 · The paper itself

Abstract

unlabelledThe regulation of the interferon type I (IFN-I) response has been shown to rely on posttranslational modification by ubiquitin (Ub) and Ub-like interferon-stimulated gene product 15 (ISG15) to stabilize, or activate, a variety of IFN-I signaling and downstream effector proteins. Unlike Ub, which is almost perfectly conserved among eukaryotes, ISG15 is highly divergent, even among mammals. Since zoonotic viruses rely on viral proteins to recognize, or cleave, ISG15 conjugates in order to evade, or suppress, innate immunity, the impact of ISG15 biodiversity on deISGylating proteases of the ovarian tumor family (vOTU) from nairoviruses was evaluated. The enzymatic activities of vOTUs originating from the Crimean-Congo hemorrhagic fever virus, Erve virus, and Nairobi sheep disease virus were tested against ISG15s from humans, mice, shrews, sheep, bats, and camels, which are mammalian species known to be infected by nairoviruses. This along with investigation of binding by isothermal titration calorimetry illustrated significant differences in the abilities of nairovirus deISGylases to accommodate certain species of ISG15. To investigate the molecular underpinnings of species preferences of these vOTUs, a structure was determined to 2.5 Å for a complex of Erve virus vOTU protease and a mouse ISG15 domain. This structure revealed the molecular basis of Erve virus vOTU's preference for ISG15 over Ub and the first structural insight into a nonhuman ISG15. This structure also revealed key interactions, or lack thereof, surrounding three amino acids that may drive a viral deISgylase to prefer an ISG15 from one species over that of another. IMPORTANCE: Viral ovarian tumor domain proteases (vOTUs) are one of the two principal classes of viral proteases observed to reverse posttranslational modification of host proteins by ubiquitin and interferon-stimulated gene product 15 (ISG15), subsequently facilitating downregulation of IFN-I signaling pathways. Unlike the case with ubiquitin, the amino acid sequences of ISG15s from various species are notably divergent. We illustrate that vOTUs have clear preferences for ISG15s from certain species. In addition, these observations are related to the molecular insights acquired via the first X-ray structure of the vOTU from the Erve nairovirus in complex with the first structurally resolved nonhuman ISG15. This information implicates certain amino acids that drive the preference of vOTUs for ISG15s from certain species.

Indexed as

AnimalsCrystallography, X-RayHumansModels, MolecularNairovirusPeptide HydrolasesProtein BindingProtein ConformationProteolysisUbiquitinsPeptide HydrolasesUbiquitins

Identifiers

PMID27412597
PMCPMC5008091
OpenAlexW2469871375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.